Table 3: Ranking for all the outcomes of the interventions included at 12 or 16 weeks in the network meta-analysis.

InterventionsPASI 75PASI 100sPGA 0/1 or IGA 0/1 or PGA 0/1AEssAEsDiscontinuations due to AEs
SUCRA (%)PrBestMeanRankSUCRA (%)PrBestMeanRankSUCRA (%)PrBestMeanRankSUCRA (%)PrHighest riskMeanRankSUCRA (%)PrHighest riskMeanRankSUCRA (%)PrHighest riskMeanRank

Brodalumab 140 mg22.80.011.063.40.55.832.00.09.838.10.09.038.40.19.054.20.67.0
Brodalumab 210 mg62.50.35.985.028.42.965.40.15.523.70.010.963.93.85.763.00.95.8
Guselkumab 100 mg28.50.010.361.46.06.031.40.09.963.41.35.849.43.37.632.10.29.8
Guselkumab 50 mg38.70.49.055.94.36.733.40.09.776.230.14.125.93.510.684.636.73.0
Ixekizumab 80 mg Q2W93.053.41.983.332.73.286.513.32.87.50.013.050.83.17.414.80.012.1
Ixekizumab 80 mg Q4W81.50.53.476.812.94.075.70.04.24.50.013.427.50.510.410.70.012.6
Placebo0.00.014.00.00.014.00.00.014.067.30.05.359.40.16.339.70.08.8
Risankizumab 150 mg62.30.45.971.36.44.766.70.45.367.65.35.292.861.51.992.653.22.0
Secukinumab 150 mg73.50.04.4310.110.085.70.02.922.70.011.030.70.410.043.50.28.4
Secukinumab 300 mg89.943.12.362.48.35.998.186.01.333.90.09.635.60.99.442.20.18.5
Tildrakizumab 100 mg33.20.29.721.90.411.222.30.011.188.827.92.570.818.94.858.64.56.4
Tildrakizumab 200 mg42.21.78.520.00.011.434.70.29.590.231.32.341.11.28.735.40.49.4
Ustekinumab 45 mg27.40.010.433.10.09.725.40.010.741.00.08.761.10.66.179.03.03.7
Ustekinumab 90 mg44.50.08.234.50.09.542.80.08.475.24.14.252.52.17.249.70.27.5

SUCRA: surface under the cumulative ranking; PrBest: probability of best treatment; PrHighest risk: probability of the highest risk of AEs; PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events; Q2W: every 2 weeks; Q4W: every 4 weeks.